Weight Loss GLP-1 Peptides Wholesales Price Liraglutide CAS 204656-20-2 with Fast Shipping Safe Delivery

Sales manager:Mandy
whatsapp：+8617268825104
Email:Mandy@xtmingheng.com

What is Liraglutide ?

Liraglutide is a transparent, colorless solution. The dosage form is subcutaneous injection. After more than 10 years of research and development, liraglutide has many functions such as promoting pancreatic cell regeneration, lowering blood sugar, reducing weight and protecting the cardiovascular system. It is used to treat type 2 diabetes under the trade name Victoz* and is used to treat chronic obesity under the trade name Saxend* as a supplement to diet control and physical exercise. Liraglutide is an acylated human glucagon-like peptide-1 (GLP-1) receptor agonist, which has 97% amino acid sequence homology with endogenous human GCPhemicalbookLP-1 (7-37), retains all the biological activity of GLP-1, and has GLP-1 receptor agonism. Through expression in recombinant DNA of brewer's yeast, its molecular structure differs from the natural GLP-1 molecule by only one amino acid, and the structure only makes the following two modifications to GLP-1: the 34th lysine is replaced by arginine, and a glutamic acid-mediated 16-carbon palmitoy* fatty acid side chain is added to the 26th lysine.

1. Liraglutide is like endogenous GLP-1, binding to and activating the GLP-1 receptor, a cell surface receptor that can activate adenylate cyclase through excitatory G protein Gs coupling. Endogenous GLP-1 has a half-life of 1.5 to 2 minutes and is easily degraded by two widely existing endogenous enzymes, dipeptidyl peptidase 4 (DPP-4) and neutral endopeptidase (NEP). Compared with natural GLP-1, liraglutide is relatively stable, with a plasma half-life of 13 hours after subcutaneous administration of Chemicalbook. This change in half-life is attributed to the modification of liraglutide's structure. Due to the presence of fatty acid side chains, on the one hand, the hydrophobicity of palmiti* acid self-associates into a heptamer, slowing down the absorption at the subcutaneous injection site; on the other hand, after absorption into the blood, it increases its binding to plasma albumin, forming a slow-release reservoir, temporarily avoiding contact with endogenous enzymes and slowing down release, prolonging the absorption and distribution time in the body, and significantly prolonging the half-life compared with natural GLP-1.

2. App.
3. 
4. Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic
   weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese),
   or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
5. Liraglutide Peptide Benefits
6. In common to various degrees with other GLP-1 receptor agonists,liraglutide has advantages over more traditional therapies for type 2 diabetes:
   1. Liraglutide acts in a glucose-dependent manner, meaning Liraglutide will stimulate insul.in secretion only when blood glucose levels are higher than normal, preventing "overshoot".Consequently, Liraglutide shows negligible risk of hypoglycemia.
   2. Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
   3. Liraglutide decreases appetite and inhibits body weight gain,as shown in a head-to-head study versus glimepiride.
   4. Liraglutide lowers blood triglyceride levels.
7. 

Xingtai xinkaiyue Technology Co., Ltd. was founded in 2019 has strong research and development capabilities and superb synthesis technology, as well as advanced quality control measures. We effectively promote joint ventures and cooperation with major enterprises and manufacturers, and serve the society and the majority of users with the idea of industrialized development. We always adhere to the market demand-oriented, and constantly synthesize new chemical products and pharmaceutical intermediates with high technical content, mainly exported to the United States, India, South Africa, Nigeria and many other countries and regions, with rich experience in export, to ensure the safety of transportation, and to be able to let every customer receive the goods safely as early as possible.

Related certifications

 OPTIMIZED, AUTOMATED HIGH-YIELD PRODUCTION

ROBUST PROCESSES AND SUPPLY SECURITY